- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Alan Menter Discusses 2022 Psoriasis Guideline Updates
Alan Menter, MD, chairman of dermatology, Baylor University Medical Center, discussed some of the updated psoriasis guidelines at the 2022 American Academy of Dermatology Annual Meeting.
Alan Menter, MD, chairman of dermatology, Baylor University Medical Center, discussed some of the updated psoriasis guidelines at the 2022 American Academy of Dermatology Annual Meeting.
Transcript
What are some of the updated psoriasis guidelines and recommendations for 2022, in relation to cardiovascular comorbidities?
The old theory that coronary artery disease is just caused by cholesterol is no longer true; it's caused by inflammation. Inflammation in the coronary artery is very similar to the inflammation in psoriasis, so improving the skin, we do believe, will improve coronary artery disease.
I chaired—co-chaired, there was 2 of us who chaired—the guidelines that we published in 2019 and 2020 in JAAD [Joint American Academy of Dermatology], and we had 6 papers, all of which were about 70 pages long. One of the guidelines related to coronary artery disease. We are relatively up to date with the fact that coronary artery disease is now inflammation driven, very similar inflammation to psoriasis, and not just driven by cholesterol.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More
